Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Infectious Diseases

Set Alert for Infectious Diseases

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: Boehringer best in MASH?; biopharma funding on an upswing?; Moderna’s combo jab; clinical trial recover from pandemic; and Astellas’s US commercial head speaks. 

Financing Vaccines

Moderna Pips Pfizer/BioNTech In Combo Jab Race

The company reported a late-stage success with its COVID-19 and flu combo vaccine, and says it can hit the market next year.

Clinical Trials Vaccines

Shionogi, Qpex Agree On Anti-Infective-Focused US R&D Site

Shionogi says first major US R&D site will enhance capabilities for both Shionogi and its 2023 acquisition Qpex, which prompted the Japanese firm to build on the San Diego company's close research collaborations with US government organizations.

Research & Development Strategy

Vir Hopes To Take On Gilead’s Hepcludex After Positive Early Hepatitis D Results

The biotech presented preliminary data on chronic hepatitis D from the Phase II SOLSTICE study of tobevibart and elebsiran at the EASL meeting.

Clinical Trials Biologics

A Job Well Done: AstraZeneca Bids Adieu To Vaxzevria As Demand Dries Up

The voluntary withdrawal of the license for the UK major's COVID-19 vaccine is due to a surplus of available updated jabs from other companies that target new variants and is not connected to the mis- and disinformation being peddled on the internet and elsewhere on very rare adverse events.

Coronavirus COVID-19 Business Strategies

BioNTech Ramps Up Spending To Launch 10 Pivotal Cancer Studies In 2024

As COVID-19 vaccine sales decline, the company is investing billions in a diverse oncology pipeline including antibody drug conjugates, immunotherapy and cancer vaccines

Clinical Trials Commercial

Emergex Goes To Battle Against ‘The Nasties’

Emerging Company Profile: The eight-year-old vaccine firm is planning clinical trials in the Philippines and Brazil to see how its synthetic viral peptide vaccine technology stands up against coronaviruses and dengue fever.

Emerging Company Profile Vaccines

Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative

Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.

Business Strategies Financing

Chinese Firms Up Their Game In Novel Flu Antiviral Development

Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.

China Research & Development

Key Activist Investor Throws Shade At Novavax Over COVID-19 Vaccines

Shah Capital Management said Novavax could tap the estimated 100 million Americans uncomfortable with mRNA vaccines, such as those from Pfizer/BioNTech and Moderna.

Vaccines Infectious Diseases

Abrysvo Data In Younger Adults Could Give Pfizer An Edge Over GSK

Pfizer plans to use the positive Phase III data in adults 18-59 to expand use of the RSV vaccine.

Infectious Diseases Vaccines
See All